lorigerlimab + docetaxel + Prednisone
Phase 2ActiveDevelopment Stage
Androgen-Independent Prostatic Cancer
Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Immunotherapy, Immune Checkpoint Inhibitor, Inhibitory Checkpoint Molecule
Sep 28, 2023 → Mar 1, 2026
About lorigerlimab + docetaxel + Prednisone
lorigerlimab + docetaxel + Prednisone is a phase 2 stage product being developed by MacroGenics for Androgen-Independent Prostatic Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05848011. Target conditions include Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05848011 | Phase 2 | Active |
Competing Products
1 competing product in Androgen-Independent Prostatic Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| cetuximab + Mitoxantrone | Eli Lilly | Phase 2 | 52 |